Apigenin (4′,5,7-trihydroxyflavone) is a naturally occurring flavonoid concentrated in chamomile, parsley, celery, and a range of other edible plants. It has been studied across multiple cancer types—not because it cures cancer, but because laboratory and animal research suggests it may interfere with several biological processes that allow cancer cells to proliferate, evade immune detection, and resist programmed cell death.
This article summarizes what peer-reviewed preclinical research has found about apigenin’s proposed role in cancer biology. The vast majority of available evidence comes from cell-culture and animal models; large-scale human clinical trials are limited. Nothing here constitutes medical advice or a treatment recommendation. These statements have not been evaluated by the FDA, and apigenin is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before using apigenin if you have a cancer diagnosis or take prescription medications.
Key Takeaways
- Apigenin is a plant flavonoid found in chamomile, parsley, and celery that has shown anticancer activity in multiple preclinical models, but human clinical trial evidence is limited.
- Proposed mechanisms include CDK-mediated cell cycle arrest, induction of apoptosis and autophagy, mTOR/PI3K/Akt pathway suppression, and modulation of immune activity.
- Preclinical research spans prostate, breast, colon, head and neck cancers, and lymphoma—though none of these findings have been confirmed in large human trials.
- Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 and may significantly interact with warfarin, certain statins, and benzodiazepines; physician consultation is essential before supplementing.
- Apigenin is not a proven cancer treatment or preventive agent; these statements have not been evaluated by the FDA, and this content is informational, not medical advice.
What Apigenin Is and Where It Comes From
Chamomile (Matricaria chamomilla) is among the richest dietary sources of apigenin, and a 2022 comprehensive review documented its broad therapeutic applications, including anti-inflammatory, antioxidant, and potential anti-tumor properties [10]. The compound belongs to the flavone subclass of polyphenols and is also present in meaningful concentrations in parsley, celery, and several common herbs.
After oral ingestion, apigenin undergoes significant first-pass metabolism in the liver and is partially converted to gut-microbial metabolites, resulting in modest bioavailability. Importantly, apigenin inhibits cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4, which can alter the blood concentrations of numerous medications. A 2023 pharmacokinetic review of related flavonoids confirmed that this enzyme-inhibitory profile creates clinically relevant drug interaction risks [11]. Individuals taking warfarin, certain statins, benzodiazepines, or other drugs processed by these enzymes should consult a physician before supplementing with apigenin.
Cell Cycle Arrest: Slowing Uncontrolled Division
One of the most studied anticancer mechanisms of apigenin is its capacity to disrupt the cell cycle—the tightly regulated sequence of events governing cell division. Cancer cells often bypass checkpoints that would ordinarily halt uncontrolled replication. Apigenin appears to reinstate some of those checkpoints.
In a 2001 study on breast carcinoma cell lines, apigenin induced G2/M phase arrest by modulating cyclin-CDK regulators and suppressing ERK MAP kinase activation [1]. In prostate cancer, a 2006 study using xenograft models identified CDK2 and CDK6 inhibition as central molecular targets for apigenin-induced cell cycle arrest and apoptosis [2]. These findings suggest apigenin does not simply destroy cancer cells outright; it may also limit their replication by interfering with the enzymatic machinery driving division. All findings are from laboratory and animal models, not human trials.
Apoptosis and Autophagy: Two Pathways to Cancer Cell Death
Apoptosis (programmed cell death) and autophagy (cellular self-digestion of damaged components) are two distinct processes the body uses to eliminate dysfunctional cells. Many cancers succeed partly by evolving resistance to both. Preclinical research suggests apigenin may re-sensitize cancer cells to these pathways.
A 2016 review focused specifically on apigenin’s role in inducing apoptosis and autophagy across multiple cancer types, noting that these dual mechanisms make it unusually multifaceted compared to single-pathway agents [4]. A 2017 review in Cell & Bioscience expanded on this, cataloging the range of anti-cancer effects and the signaling networks involved—including effects on Bcl-2 family proteins, caspase activation, and autophagy induction [5].
Cisplatin resistance in colorectal cancer is a significant clinical obstacle. A 2019 study found that apigenin induced autophagy and programmed cell death in cisplatin-resistant colon cancer cells while also targeting the mTOR/PI3K/Akt signaling pathway—a cascade frequently overactivated in treatment-resistant tumors [7]. These results are from in vitro and animal models and cannot be directly applied to human treatment decisions.
Cancer-Specific Research Highlights
Preclinical research into apigenin spans several cancer types. In head and neck cancers, a 2013 study examined GLUT-1 (glucose transporter 1) expression and its relevance to apigenin’s mechanism of action, noting that cancer cells depend heavily on glucose uptake and that compounds interfering with this metabolic pathway may limit tumor energy supply [3]. In diffuse large B-cell lymphoma (DLBCL), a 2020 study found that combining apigenin with abivertinib—a BTK inhibitor—produced synergistic inhibition both in cell culture and in animal models [8], suggesting potential for combination approaches, though human validation is absent.
A 2025 review of natural anti-cancer products from herbal medicine situated apigenin among a class of plant-derived compounds with documented preclinical activity, while noting that translating laboratory findings into clinical outcomes remains an open and unsolved challenge across the entire field of botanical oncology [12]. A 2017 review in Advances in Clinical and Experimental Medicine similarly cataloged the range of novel anticancer applications being explored for apigenin across tumor types, including prostate, breast, colorectal, hepatic, and cervical cancers [6].
Immune Modulation: Supporting the Body's Cancer Surveillance
Beyond direct effects on cancer cells, apigenin may influence how the immune system responds to tumors. Many cancers succeed partly by suppressing immune detection—a process called immunosurveillance evasion. A 2021 review in Current Pharmaceutical Design examined apigenin’s anticancer potential through the lens of immunoregulation, documenting its effects on T-cell activity, macrophage polarization, and inflammatory cytokine profiles [9].
The review noted that apigenin appears to modulate immune pathways in ways that could theoretically support anti-tumor immunity, adding another proposed mechanism beyond direct cytotoxicity. Whether these immunological effects translate to meaningful cancer prevention in living humans has not been established in clinical trials.
Key Limitations of the Current Evidence
The research summarized here is predominantly preclinical. Cell culture and animal studies allow scientists to isolate specific biological effects, but they do not reliably predict outcomes in humans. Drug candidates that show strong activity in vitro frequently fail in clinical trials due to differences in bioavailability, metabolism, immune context, and the inherent heterogeneity of human tumors.
Apigenin’s oral bioavailability is limited, meaning concentrations achievable through dietary intake or standard supplementation are likely far below those used in laboratory studies. Researchers are exploring delivery strategies such as liposomal encapsulation and nanoparticle carriers to improve this, but none have been validated in large human trials. Additionally, apigenin’s inhibition of CYP1A2, CYP2C9, and CYP3A4 creates real interaction risks with common medications, and caution is warranted when stacking it with other sedatives including melatonin and alcohol [11].
🛒 Where to Buy Apigenin
- Momentous Momentous ApigeninLab-tested / studied
capsules, 50 mg per capsule — Andrew Huberman’s publicly recommended brand; NSF Certified for Sport; single-ingredient, no fillers - Double Wood Supplements Apigenin 50mg
capsules, 50 mg per capsule, 120 count — High-volume value pick; third-party tested for purity; frequently top-ranked on Amazon - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 120 count — FDA-registered facility; gluten-free, non-GMO; competitive price-per-dose - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count — Established supplement brand; GMP-certified manufacturing; widely available, low cost
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence reviewed here is largely preclinical—derived from cell cultures and animal models—and does not establish apigenin as a proven cancer prevention or treatment agent in humans; controlled clinical trials are limited and none are sufficient to support therapeutic claims. Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4, creating real interaction risks with warfarin, certain statins, benzodiazepines, and other medications, so individuals on prescription drugs or with an active cancer diagnosis must consult a physician before use.
Frequently Asked Questions
How does apigenin affect cancer cell division?
Laboratory research shows apigenin can induce cell cycle arrest at the G2/M checkpoint by modulating cyclin-CDK regulators and suppressing ERK MAP kinase activation in breast carcinoma cells [1]. In prostate cancer xenograft models, CDK2 and CDK6 were identified as key molecular targets [2]. These mechanisms have been studied in cell cultures and animals, not confirmed in human clinical trials.
Has apigenin been studied in drug-resistant cancers?
Yes, at a preclinical level. A 2019 study in cisplatin-resistant colon cancer cells found apigenin induced autophagy and programmed cell death while targeting the mTOR/PI3K/Akt signaling pathway—a cascade commonly overactivated in treatment-resistant tumors [7]. This is early-stage research and should not be interpreted as a rationale to use apigenin in place of prescribed chemotherapy.
Can apigenin be combined with cancer medications?
Preclinical data shows potential synergy. A 2020 study found apigenin combined with the BTK inhibitor abivertinib produced synergistic suppression of diffuse large B-cell lymphoma in cell culture and animal models [8]. No human clinical trials have validated such combinations, and apigenin’s CYP enzyme inhibition creates meaningful drug interaction risks, so any combination with cancer medications requires physician oversight.
What role does the immune system play in apigenin's proposed effects?
A 2021 review documented apigenin’s effects on T-cell activity, macrophage polarization, and inflammatory cytokine profiles, suggesting it may support anti-tumor immunosurveillance [9]. This immune-modulation dimension is distinct from direct cytotoxicity, but its clinical relevance in humans has not been established in controlled trials.
Is dietary apigenin from chamomile or parsley meaningful?
Chamomile is one of the most concentrated dietary sources of apigenin, and its therapeutic applications including potential anti-tumor properties are well-documented [10]. However, dietary concentrations are substantially lower than those used in laboratory studies, so drawing direct equivalences between chamomile consumption and anticancer effects seen in cell culture is not scientifically supported.
Who should avoid or use apigenin supplements cautiously?
Anyone taking warfarin, certain statins, benzodiazepines, or other drugs metabolized by CYP1A2, CYP2C9, or CYP3A4 should consult a physician first, as apigenin inhibits these enzymes and can alter medication blood levels [11]. Caution is also warranted when combining with sedatives including melatonin and alcohol. Pregnant individuals and those undergoing active cancer treatment should discuss use with their care team before starting any flavonoid supplement.
References
- Yin F et al. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer research (2001). PMID 11299771
- Shukla S et al. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Molecular cancer therapeutics (2006). PMID 16648554
- Bao YY et al. Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers. Future oncology (London, England) (2013). PMID 23980682
- Sung B et al. Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy. Journal of cancer prevention (2016). PMID 28053955
- Yan X et al. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell & bioscience (2017). PMID 29034071
- Kowalczyk A et al. Insights into novel anticancer applications for apigenin. Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2017). PMID 29211364
- Chen X et al. Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway. Journal of B.U.ON. : official journal of the Balkan Union of Oncology (2019). PMID 31127995
- Huang S et al. Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. Journal of Cancer (2020). PMID 32127939
- Xu L et al. The Anticancer Potential of Apigenin Via Immunoregulation. Current pharmaceutical design (2021). PMID 32660399
- Sah A et al. A Comprehensive Study of Therapeutic Applications of Chamomile. Pharmaceuticals (Basel, Switzerland) (2022). PMID 36297396
- Farasati Far B et al. Achillea millefolium: Mechanism of action, pharmacokinetic, clinical drug-drug interactions and tolerability. Heliyon (2023). PMID 38076118
- Cui D et al. Natural anti-cancer products: insights from herbal medicine. Chinese medicine (2025). PMID 40490812
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.